secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2026-05-12T12:08:34+00:00
Accession:  0001193125-26-218240
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris Q1 net loss $10.9M; cash $104.9M; Phase 1b/2 TH103 screening patients
-----------------------------------------------------------------------------

- Net loss $10.9M in Q1 2026 vs $10.2M in Q1 2025; R&D expense $7.6M (+27% YoY).
- Cash and securities $104.9M at March 31, 2026, down from $118.0M at December 31, 2025; runway into Q4 2027.
- Patient screening underway in Phase 1b/2 multiple-ascending-dose trial of TH103 for wet AMD; data expected 1H 2027.
- New manufacturing batch completed with process enhancements reducing impurities; Phase 3 initiation on track for end of 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526218240/0001193125-26-218240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526218240/d24879d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-218240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer